Ifosfamide in the treatment of ovarian cancer.
Ifosfamide has been assessed in the treatment of ovarian cancer for more than two decades. The drug possesses well-documented but modest activity (10% to 15% range) in women with platinum/alkylating agent-resistant ovarian cancer. A potentially important ongoing clinical trial is attempting to define the level of activity of ifosfamide administered in the salvage setting to patients with advanced ovarian cancer who have been previously treated with a platinum drug plus paclitaxel but not an alkylating agent.
Markman
M
M
The Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D016879:Salvage Therapy
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin; D007069:Ifosfamide